Cue the subQ.

How do you bust the immune checkpoint inhibitor market wide open? With a tiny needle of course. The next PD-1 inhibitor vying for FDA approval is PF-06801591 (popstar name pending), which has recently proved safe and effective in none other than a monthly subcutaneous formulation. | Johnson, JAMA Oncol 2019